2023 LCRF–Daiichi Sankyo–AstraZeneca Research Grant on Antibody Drug Conjugates
Aakash Desai, MD, MPH
University of Alabama at Birmingham
Research Project:
Deciphering the ADC Code: A Proteogenomic Quest in Lung Cancer
Summary:
This research project aims to improve the treatment of Non-Small Cell Lung Cancer (NSCLC) using a special kind of therapy called Antibody-drug conjugates (ADCs). These therapies are designed to target cancer cells more precisely. However, it’s not fully understood why some patients respond better to these treatments than others. The focus of this project is to study a particular target on cancer cells, known as Trop-2, and to figure out how its presence or absence affects the success of the therapy. By examining the characteristics of cancer cells and their surrounding environment in great detail, the project hopes to find out which patients are more likely to benefit from ADCs. This could lead to more personalized and effective treatments for lung cancer.